Search - Université de Rennes Access content directly

Filter your results

10 Results
authFullName_s : Arnaud Pigneux
Image document

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study

J.-P. Gangneux , Christophe Padoin , Mauricette Michallet , Emeline Saillio , Alexandra Kumichel et al.
Journal of Fungi, 2020, 6 (4), pp.281. ⟨10.3390/jof6040281⟩
Journal articles hal-03023998v1

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Arnaud Pigneux , Jean-Luc Harousseau , Francis Witz , Mathieu Sauvezie , Marie-Christine Bene et al.
Journal of Clinical Oncology, 2010, 28 (18), pp.3028-34. ⟨10.1200/JCO.2009.26.4648⟩
Journal articles hal-00849638v1

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group

Thorsten Braun , Sophie Cereja , Sylvie Chevret , Emmanuel Raffoux , Marie Beaumont et al.
Cancer, 2015, 121 (14), pp.2393-2399. ⟨10.1002/cncr.29389⟩
Journal articles hal-01237097v1

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Lionel Adès , Xavier Thomas , Agnes Cuerci-Bres , Raffoux Emmanuel , Olivier Spertini et al.
Blood, 2015, 126 (23), pp.451
Journal articles hal-01300812v1

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

Bruno Lioure , Marie C Béné , Arnaud Pigneux , Anne Huynh , Patrice Chevallier et al.
Blood, 2012, 119 (12), pp.2943-8. ⟨10.1182/blood-2011-05-352989⟩
Journal articles hal-00849702v1

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia

Xavier Cahu , Martin Carré , Christian Recher , Arnaud Pigneux , Mathilde Hunault-Berger et al.
European Journal of Haematology, 2017, 98, pp.443-449. ⟨10.1111/ejh.12850⟩
Journal articles hal-01558818v1

Induction-related cost of patients with acute myeloid leukaemia in France.

Virginie Nerich , Bruno Lioure , Maryline Rave , Christian Recher , Arnaud Pigneux et al.
Int J Clin Pharm, 2011, 33 (2), pp.191-9. ⟨10.1007/s11096-010-9462-1⟩
Journal articles istex hal-00849659v1

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Arnaud Pigneux , Christian Récher , Marie C. Bene , Julien Asselineau , Ariane C. Mineur et al.
Blood, 2015, 126 (23)
Journal articles hal-01295674v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1